6min chapter

VJHemOnc Podcast cover image

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

VJHemOnc Podcast

CHAPTER

FDA Approval of Luspattersept for Frontline Therapy in Lower-Risk MDS

Discussion on the FDA approval of Luspattersept for frontline therapy in lower-risk MDS, comparing it to erythropoietin (EPO) and exploring the factors that influence treatment choice. The chapter also highlights the goal of treating cytopenias and anemia to improve patient outcomes and quality of life.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode